Elimination of graft versus host disease in matched allogeneic leukemic transplant recipients using CAMPATH-1.

Elimination of graft versus host disease in matched allogeneic leukemic transplant recipients using CAMPATH-1.

Opis bibliograficzny
Główni autorzy:	Slavin, S, Or, R, Weiss, L, Steiner-Zalz, D, Cividalli, G, Brautbar, C, Weshler, Z, Galun, E, Samuels, S, Galili, D
Format:	Journal article
Język:	English
Wydane:	1985

Podobne zapisy

Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1).
od: Waldmann, H, i wsp.
Wydane: (1984)

ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR LEUKEMIA USING CAMPATH-1 MONOCLONAL-ANTIBODIES AND POSTTRANSPLANT ALLOIMMUNIZATION WITH DONOR LYMPHOCYTES
od: Naparstek, E, i wsp.
Wydane: (1993)

Allogeneic bone marrow transplantation without graft-v-host disease: true tolerance of graft against the host through depletion of donor T lymphocytes pregrafting in malignant and nonmalignant disorders.
od: Slavin, S, i wsp.
Wydane: (1987)

PREVENTION OF GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR LEUKEMIA BY T-CELL DEPLETION INVITRO PRIOR TO TRANSPLANTATION
od: Slavin, S, i wsp.
Wydane: (1985)

Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies.
od: Naparstek, E, i wsp.
Wydane: (1999)

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
od: Hale, G, i wsp.
Wydane: (1988)

New approaches for the prevention of rejection and graft-vs.-host disease in clinical bone marrow transplantation.
od: Slavin, S, i wsp.
Wydane: (1986)

T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse.
od: Naparstek, E, i wsp.
Wydane: (1995)

Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases.
od: Hale, G, i wsp.
Wydane: (1994)

COMBINED USE OF CAMPATH-1G IN-VIVO AND IN THE BAG IN ALLOGENEIC BONE-MARROW TRANSPLANTATION
od: Fibbe, W, i wsp.
Wydane: (1993)

Induction of anti-leukemic responses by stimulation of leukemic CD3+ cells with allogeneic stimulator cells
od: Alejandro Pando, i wsp.
Wydane: (2018-10-01)

T-cell depletion with Campath-1H "in the bag" for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival.
od: Chakrabarti, S, i wsp.
Wydane: (2003)

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
od: Hale, G, i wsp.
Wydane: (2002)

CAMPATH-IH in multiple sclerosis.
od: Moreau, T, i wsp.
Wydane: (1996)

Campath 1 H "in the bag" is an effective method of GvHD prevention in allogeneic stem cell transplantation.
od: Potter, M, i wsp.
Wydane: (2000)

Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients.
od: Calne, R, i wsp.
Wydane: (1999)

Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression.
od: Trzonkowski, P, i wsp.
Wydane: (2006)

Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression.
od: Trzonkowski, P, i wsp.
Wydane: (2006)

Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
od: Chakrabarti, S, i wsp.
Wydane: (2004)

CAMPATH-1H for the treatment of acute rejection in kidney transplant recipients: 10 year follow-up
od: Clatworthy, MR, i wsp.
Wydane: (2007)

Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients.
od: Calne, R, i wsp.
Wydane: (1998)

CAMPATH: from concept to clinic.
od: Waldmann, H, i wsp.
Wydane: (2005)

Evaluation of non-myeloablative conditioning combining beam with in vivo pre-transplant Campath-IG for allogeneic transplantation in patients with lymphoma.
od: Russell, N, i wsp.
Wydane: (1999)

CAMPATH-1 antibodies in stem-cell transplantation.
od: Hale, G, i wsp.
Wydane: (2001)

Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
od: Clatworthy, MR, i wsp.
Wydane: (2009)

Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality.
od: Chakrabarti, S, i wsp.
Wydane: (2002)

Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation.
od: Heit, W, i wsp.
Wydane: (1986)

Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
od: Williams, R, i wsp.
Wydane: (2000)

CAMPATH-1H in inflammatory arthritis.
od: Watts, R, i wsp.
Wydane: (1993)

Specificity of monoclonal antibody Campath-1.
od: Hale, G, i wsp.
Wydane: (1988)

The CAMPATH-1 antigen (CDw52).
od: Hale, G, i wsp.
Wydane: (1990)

Allogeneic stem cell transplantation for lymphoproliferative disease using BEAM-Campath conditioning: An effective regime with low procedure-related toxicity.
od: Cull, G, i wsp.
Wydane: (1999)

Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection.
od: Hale, G, i wsp.
Wydane: (1996)

Graft failure in allogeneic hematopoietic stem cell recipients: diagnosis and treatment
od: U. V. Maslikova, i wsp.
Wydane: (2023-03-01)

Analysis of the results of allogeneic hematopoietic stem cell transplantation depending on HLA matching of the unrelated donor / recipient pair
od: Ye. V. Kuzmich, i wsp.
Wydane: (2015-01-01)

Analysis of the results of allogeneic hematopoietic stem cell transplantation depending on HLA matching of the unrelated donor / recipient pair
od: Ye. V. Kuzmich, i wsp.
Wydane: (2015-01-01)

Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells.
od: Jérome Kluza, i wsp.
Wydane: (2011-01-01)

Sequential allogeneic and autologous CAR-T–cell therapy to treat an immune-compromised leukemic patient
od: Jian-Ping Zhang, i wsp.
Wydane: (2018-07-01)

Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity.
od: Cull, G, i wsp.
Wydane: (2000)

Low T-Cell Responses to Mitogen Stimulation Predicts Poor Survival in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
od: Michelle K. Yong, i wsp.
Wydane: (2017-11-01)